Pharsight

1. List of Akynzeo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6297375	HELSINN HLTHCARE	4-phenyl-pyridine derivatives	Mar, 2023 (a month from now)
US10676440	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (12 years from now)
US10233154	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (12 years from now)
US9951016	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (12 years from now)
US10961195	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623826	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US9186357	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US9943515	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US8951969	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US10828297	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Dec, 2030 (7 years from now)
US9271975	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Sep, 2031 (8 years from now)

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL